Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07002801

Application of Remimazolam Combined With Esketamine in Painless Gastroscopy and Colonoscopy in Elderly Patients

The objective of this clinical trial is to assess the feasibility of the remimazolam combined with esketamine OFA (opioid-free anesthesia) protocol for painless gastroscopy and colonoscopy in elderly patients and to determine if it is non-inferior to the traditional OA (opioid-containing anesthesia) protocol. The main questions it aims to answer are:

* Is the remimazolam combined with esketamine protocol feasible for painless gastroscopy and colonoscopy in elderly patients? * Is the OFA protocol superior to the OA protocol?

Participants will:

* During anesthesia induction, the experimental group will receive remimazolam combined with esketamine for anesthesia, while the control group will receive remimazolam combined with remifentanil. * Record respiratory and circulatory indicators and adverse reaction times.

Recruiting

Interested in participating?

Request Info

Key information

Age range

65 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

About this study

Elderly patients undergoing painless gastroenteroscopy were randomly divided into remazolam + esketamine group (RE group) and remazolam + remifentanil group (RR group). In RE group, anesthesia induction was as follows: Remazolam 0.2mg/kg, esketamine 0.15mg/kg, lidocaine 0.5mg/kg, changtonine 0.2mg. RR group: Anesthesia induction: remazolam 0.2mg/kg, remifentanil 0.2μg/kg, lidocaine 0.5mg/kg, Changtonine 0.2mg. Remazolam and esketamine/remifentanil were added during the operation according to the depth of sedation and movement of the patient. The outcome measures included success rate of sedation, incidence of respiratory depression, incidence of hypotension and bradycardia, postoperative recovery time, incidence of adverse reactions, postoperative satisfaction of patients and gastroenteroscopists.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients undergoing painless gastroenteroscopy in outpatient clinics;
  • aged 65 years and above;
  • American Society of Anesthesiologists (ASA) grades I - III.

Exclusion criteria

  • Patients with abnormal liver or kidney function;
  • known respiratory or endocrine diseases;
  • Patients with uncontrolled hypertension and NYHA classification Ⅲ-Ⅳ;
  • Taking monoamine oxidase inhibitors, sedatives, analgesics, hypnotics, antipsychotics, antiemetics or antidepressants;
  • Addiction to tobacco and alcohol;
  • Patients allergic to the investigational drug;
  • expected difficult airway;
  • Body mass index (BMI) >35kg/m^2;
  • Have participated in other clinical trials within the past three months;
  • Patients with psychosocial illness or cognitive dysfunction and inability to cooperate or communicate.

Treatment and study plan

remimazolam-remifentanil

Combination Product

For elderly patients scheduled for elective painless gastro-intestinal endoscopy, remimazolam 0.2mg/kg and remifentanil 0.2ug/kg are used for anesthesia induction. During the operation, the doses are adjusted according to the depth of sedation of the patients.

remimazolam-esketamine

Combination Product

For elderly patients scheduled for painless gastroenterological endoscopy, remimazolam 0.2mg/kg and esketamine 0.15mg/kg are used for anesthesia induction. During the operation, the dosage is adjusted according to the patient's level of sedation.

Primary outcomes

  1. Sedation success rate

    Time frame: From the start of anesthesia induction to the end of the surgery

    Successful sedation:① The patient underwent painless gastroenteroscopy;②During anesthesia induction, a single remazolam is not enough to achieve sufficient sedation depth, and it needs to be remedied, and the number of remediations within 15min is less than 5 times; Intraoperative supplementary times ≤5 times within any 15min.③ The patient did not use rescue drugs;Sedation success rate: Number of patients successfully sedated/total number of patients included in the data analysis for this group

  2. Incidence of hypotension

    Time frame: From the start of anesthesia induction to the end of the surgery

    Hypotension: systolic blood pressure below 80% of baseline systolic blood pressure or MAP below 80% of baseline MAP; Incidence of hypotension: Number of patients with intraoperative hypotension/total number of patients included in the data analysis for this group

Secondary outcomes

  1. degree of blood oxygen saturation

    Time frame: From the start of anesthesia induction to the end of the surgery

    The blood oxygen saturation was recorded every 2 minutes during the operation. The maximum value is 100. An event where blood oxygen saturation drops below 90 is described as respiratory depression.

  2. respiratory rate

    Time frame: From the start of anesthesia induction to the end of the surgery

    The respiratory rate was recorded every 2 minutes during the operation. The normal breathing rate is 12 to 20 breaths per minute.

  3. bispectral index

    Time frame: From the start of anesthesia induction to the end of the surgery

    During the surgery, the bilateral frequency index of brain electricity was recorded every 2 minutes. The bispectral index of electroencephalogram is mainly used to assess the depth of sedation, the effect of anesthesia and the state of consciousness. Its value range is from 0 to 100. The higher the value, the higher the degree of consciousness; the lower the value, the deeper the degree of brain inhibition.

  4. Heart rate

    Time frame: From the start of anesthesia induction to the end of the surgery

    The heart rate was recorded every 2 minutes during the operation. The normal heart rate is 60 to 100 beats per minute.

  5. Blood pressure

    Time frame: From the start of anesthesia induction to the end of the surgery

    The blood pressure was recorded every 2 minutes during the operation.

  6. Modified Observer's Assessment of Alertness/Sedation Scale

    Time frame: From the start of anesthesia induction to the end of the surgery

    The MOAA/S, which stands for Modified Observer's Assessment of Alertness/Sedation Scale, assesses the patient's response to sounds or physical stimuli and is scored on a scale of 6 levels:

    Level 5: Normal alertness, quick response to normal tone of voice; Level 4: Slow response to normal tone of voice; Level 3: Only responds to loud or repeated calls; Level 2: Only responds to slight shaking or tactile stimuli; Level 1: No response to slight shaking or tactile stimuli, but responds to pain stimuli (such as pinching the trapezius muscle); Level 0: No response to pain stimuli. During the surgery, the MOAA/S value was recorded every 2 minutes.

  7. Hiccup

    Time frame: From the start of anesthesia induction to the end of the surgery

    Level 0: No hiccups; Level 1: Single mild hiccup; Level 2: Multiple mild hiccups, not affecting the surgical operation (≤ 5 seconds); Level 3: Severe hiccups, affecting the surgical operation (> 5 seconds).

  8. cough

    Time frame: From the start of anesthesia induction to the end of the surgery

    Level 0: No choking coughing action; Level 1: A single mild choking coughing action; Level 2: Multiple mild choking coughing actions, which do not affect the surgical operation (≤ 5 seconds); Level 3: Severe coughing (> 5 seconds).

  9. Physical movement

    Time frame: From the start of anesthesia induction to the end of the surgery

    Level 1: No activity: Level 2: Slight activity, does not affect operation: Level 3: Obvious activity, has some impact on surgical operation; Level 4: Limb twisting, significantly affects operation.

  10. Grade of abdominal wall muscle stiffness

    Time frame: From the start of anesthesia induction to the end of the surgery

    No; moderate (by pressing the abdomen, the abdominal wall muscles become stiff, which affects the colonoscopy examination); Severe (by pressing the abdomen, the abdominal wall muscles become stiff, severely affecting the colonoscopy examination)

  11. time index

    Time frame: From the start of anesthesia induction to the end of the surgery

    The induction time of anesthesia is the period from the start of administering remimazolam and remifentanil (esketamine) until the patient loses consciousness and is ready for surgery. The operation time is the duration from the beginning of the gastroscopy procedure to the end of the colonoscopy. The period of full consciousness is from the last administration of anesthetic drugs until the patient regains consciousness. The anesthesia recovery time is the duration from the time the patient regains consciousness to the time when the Aldrete score reaches 9 points.

  12. The usage of anesthetic drugs

    Time frame: From the start of anesthesia induction to the end of the surgery

    Record the consumption amounts of lidocaine, esketamine, remifentanil and remimazolam during the operation

  13. Adverse event

    Time frame: From the induction of anesthesia to the end of the surgery, and from the end of the surgery to the time when the patient leaves the anesthesia recovery room.

    Adverse events include intraoperative respiratory depression, hypotension, hypertension, bradycardia, tachycardia, arrhythmia, hiccups, choking cough, body movement, abdominal wall rigidity; postoperative nausea, vomiting, headache, dizziness, visual impairment, hallucination, intraoperative awareness, etc.

  14. The satisfaction of patients

    Time frame: Ask the patient after they regain consciousness.

    The patient's satisfaction was measured using the visual analogue scale method. A 10-cm movable ruler with 10 marks was used, with the two ends marked as 0 and 10 respectively. The patient was asked to mark the corresponding position on the ruler that represented their satisfaction level. 0 represented extreme dissatisfaction and 10 represented very satisfaction.

  15. The satisfaction of doctor

    Time frame: At the end of the surgery

    The satisfaction of the doctors was measured using the visual analogue scale method. A 10-cm movable ruler was used, marked with 10 graduations, with the two ends representing 0 points and 10 points respectively. The doctors were asked to mark the corresponding position on the ruler that best represented their satisfaction level. 0 points indicated extreme dissatisfaction, while 10 points indicated very high satisfaction.

  16. Patient pain score

    Time frame: After the patient regained consciousness

    The patient's pain score is classified into four levels: no pain, mild abdominal distension pain (pain is present only when pressed; no pain when not pressed), moderate abdominal pain (pain persists even when not pressed, but is tolerable), and severe abdominal pain (pain is unbearable).

  17. Telephone Interview for Cognitive Status

    Time frame: Before the start of the surgery, after the anesthesia wore off, and on the seventh day after the surgery

    The Telephone Interview for Cognitive Status is a tool used to assess cognitive functions, especially suitable for remote screening of cognitive impairments. TICS is a standardized telephone interview scale that evaluates the cognitive functions of the subjects through questions, including orientation, memory, language ability, calculation ability, etc. It consists of 13 items, with a total score ranging from 0 to 50, and a lower score indicates more severe cognitive impairment.

  18. The Confusion Assessment Method---CAM

    Time frame: The seventh day after the operation

    • Applicable population: Elderly patients, especially those who have undergone surgery or have cognitive impairments.
    • Assessment items: It includes 11 indicators, such as acute onset, attention disorder, disordered thinking, disorientation, etc. Each item is scored from 0 to 3 or 0 to 4 points.
    • Diagnostic criteria: Total score: Below 19 points indicates no delirium, 20 to 22 points indicates suspicion, and above 22 points confirms the diagnosis.

Study contacts

Contact information is provided by the study sponsor or research team.

LIU Shujie LIU

CONTACT

[email protected]

+86 138 4508 0390

SHI Xiaoqian SHI

CONTACT

[email protected]

+86 188 3424 7923

Sponsors and collaborators

Lead sponsor

Harbin Medical University

Other

Collaborators

  • First Affiliated Hospital of Harbin Medical University

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2028
First posted
Jun 4, 2025
Registry last updated
Jun 4, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.